Atrial fibrillation induced by gemcitabine treatment in a 65-year-old man

Tavil Y., Arslan U., Okyay K., Sen N., Boyaci B.

ONKOLOGIE, cilt.30, sa.5, ss.253-255, 2007 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 30 Sayı: 5
  • Basım Tarihi: 2007
  • Doi Numarası: 10.1159/000100930
  • Dergi Adı: ONKOLOGIE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.253-255
  • Anahtar Kelimeler: gemcitabine, chemotherapy, atrial fibrillation, CELL LUNG-CANCER, PHASE-II, SAFETY PROFILE, TOXICITY, MANIFESTATION
  • Gazi Üniversitesi Adresli: Evet

Özet

Background: Gemcitabine, a pyrimidine analogue, is a cell cycle-specific antineoplastic agent that is structurally related to cytarabine. Major side effects of the treatment with gemcitabine are hepatic dysfunction, myelo-suppression, renal impairment and pulmonary toxicity. Development of atrial fibrillation (AF) during gemcitabine treatment is very rare and was reported in only 2 case reports in the literature. Case Report: We report the case of a 65-year-old man who developed AF under gemcitabine therapy for non-small cell lung cancer (stage IIIB). In this patient, AF was intrinsically associated with chemotherapy administration which triggered arrhythmia. Conclusion: Although AF caused by gemcitabine appears to be rare, patients at risk of developing atrial fibrillation should be closely monitored for this complication.